Parabilis Medicines Seeks $476M in IPO
Parabilis Medicines (PBLS), a cancer drug developer with backing from Regeneron Pharmaceuticals (REGN), plans to raise up to $476 million through its initial public offering. The company filed an amended S-1 registration statement for the U.S.-based IPO.
Tickers: $REGN
Topics: biotech ipos Regeneron partnership